I kliniske undersøgelser med en dosering på 250 mikrogram (totalt 633 patienter) var de hyppigst observerede bivirkninger, i det mindste muligvis relaterede til Aloxi, hovedpine (9%) og obstipation (5%).
In clinical studies at a dose of 250 micrograms (total 633 patients) the most frequently observed adverse reactions, at least possibly related to Aloxi, were headache (9%) and constipation (5%).